06 September 2023 | News
IVI and EuBiologics sign Memorandum of Understanding with DEK Vaccines to support fill and finish of oral cholera vaccine in Ghana
South Korea-based International Vaccine Institute (IVI), EuBiologics, and DEK Vaccines have signed a Memorandum of Understanding (MoU) at Ghana’s National Vaccine Institute establishing a new partnership to support the fill and finish of the EuBiologics oral cholera vaccine (OCV) in DEK’s manufacturing facilities in Ghana.
IVI, a non-profit international organisation with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, developed OCV and holds the intellectual property for the vaccine, transferring the technology to manufacturers around the world, especially Developing Countries Vaccine Manufacturers.
To date, IVI has or is currently transferring OCV technology to six manufacturers, including EuBiologics in the Republic of Korea who is currently the largest producer of OCV and will be the only supplier to the global health market by the end of the year.
Through this new tripartite partnership, IVI and EuBiologics plan to transfer OCV fill and finish technology to DEK, enabling domestic production, purchase, and sales of OCV. Additionally, the MoU outlines further collaborative activities including support for OCV clinical trials in Ghana and other African countries, sufficiently scaling up vaccine production capacity, and gaining regulatory approvals.